Skip to main content

Table 1 Response rate and prevalence of PRKDC mutations in data cohorts from several clinical cohorts [69]

From: Role of PRKDC in cancer initiation, progression, and treatment

Paper Cancer Sample size Sample with PRKDC mutation Responder with PRKDC Response rate (%)
Synder et al. Melanoma 64 2 (3.1%) 2 100
Rizvi et al. NSCLC 31 3 (9.7%) 2 66.70
Van Allen et al. Melanoma 110 9 (8.2%) 4 55.60
Anagnostou et al. NSCLC 4 1 (25%) 1 100
Maio et al. Renal cell carcinoma 98 2 (2.0%) 1 50
Riaz et al. Melanoma 65 2 (3.1%) 1 50